TWA
VINC

TCI Wealth Advisors’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History

TCI Wealth Advisors’s Portfolio VINC Stock Details VINC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3
Closed -$1K – 2560
2021
Q3 		$1K Buy
+3
New +$875 ﹤0.01% 2333

Other funds holding VINC

SRC
Sage Rhino Capital Menlo Park, California $535M AUM 24.07% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

TCI Wealth Advisors's VINC Position: Q4 2021 in Review

TCI Wealth Advisors sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q4 2021, closing a stake of 3 shares — an estimated $1K sold.

TCI Wealth Advisors first reported a position in VINC in Q3 2021 and held it in 1 quarter. The position peaked at $1K in Q3 2021. 55 funds tracked by Wall St. Rank hold VINC as of Q4 2021.

  • TCI Wealth Advisors reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • TCI Wealth Advisors sold 3 Vincerx Pharma, Inc. Common Stock shares in Q4 2021, an estimated $1K.
  • TCI Wealth Advisors first reported a position in Vincerx Pharma, Inc. Common Stock in Q3 2021 and held it in 1 quarter.
  • TCI Wealth Advisors's Vincerx Pharma, Inc. Common Stock position peaked at $1K in Q3 2021.
  • 55 funds tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q4 2021.

Based on TCI Wealth Advisors's 13F filing for Q4 2021, filed 24 Jan 2022.